Kristin M. Wall
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kristin M. Wall has a total of 353 co-authors. Here are the top co-authors by number of shared publications:
Amanda Tichacek
Rwanda Zambia Health Research Group (RZHRG), Department of Pathology and Laboratory Medicine, School of Medicine, Emory University, Atlanta, Georgia USA
34 shared publicationsSusan Allen
Affiliations Rwanda Zambia HIV Research Group, Department of Pathology and Laboratory Medicine, School of Medicine and Hubert Department of Global Health, Rollins School of Public Health, Laney Graduate School, Emory University, Atlanta, Georgia, United States of America, Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, United States of America
31 shared publicationsEtienne Karita
Projet San Francisco (PSF)/Center for Family Health Research (CFHR), Kigali, Rwanda
29 shared publications- Susan Allen
Rwanda Zambia Health Research Group, Department of Pathology & Laboratory Medicine, School of Medicine, Emory University, Atlanta, USA
24 shared publications Rachel Parker
Rwanda Zambia Health Research Group (RZHRG), Department of Pathology and Laboratory Medicine, School of Medicine, Emory University, Atlanta, Georgia USA
23 shared publicationsRosine Ingabire
Projet San Francisco (PSF)/Center for Family Health Research (CFHR), Kigali, Rwanda
23 shared publications
Latest Publications
- Open Access
Implementation of a Large-Scale Ebola Vaccination Campaign in Rwanda
Background/Objectives: Ebola Virus Disease (EVD) remains a public health threat in sub-Saharan Africa. The 10th Ebola outbreak in the Democratic Republic of the Congo (DRC) in 2018–2020 led the Rwanda Ministry of Health to launch a large-scale Ebola vaccination campaign using the two-dose Ad26.ZEBOV and MVA-BN-Filo regimen. The campaign was implemented by local organizations, the Center for Family Health Research and Rinda Ubuzima, in partnership with the Rwanda Biomedical Center. Methods: The campaign targeted those who live near or routinely cross the Rwanda/DRC border and unvaccinated first responders. Children p < 0.05) to be lost between the first and second dose. Most individuals who were ineligible for the second dose were women who fell pregnant after the first dose. Conclusions: Findings highlight that a large-scale vaccination campaign, including remote areas, is feasible with high adherence despite the concurrent COVID-19 pandemic. Early stakeholder engagement and local leadership were critical to success. Future studies of reasons for non-adherence, as well as strategies to integrate family planning into campaign activities to reduce ineligibility due to pregnancy, are warranted.
Open AccessImplementation of a Large-Scale Ebola Vaccination Campaign in Rwanda
Background/Objectives: Ebola Virus Disease (EVD) remains a public health threat in sub-Saharan Africa. The 10th Ebola outbreak in the Democratic Republic of the Congo (DRC) in 2018–2020 led the Rwanda Ministry of Health to launch a large-scale Ebola vaccination campaign using the two-dose Ad26.ZEBOV and MVA-BN-Filo regimen. The campaign was implemented by local organizations, the Center for Family Health Research and Rinda Ubuzima, in partnership with the Rwanda Biomedical Center. Methods: The campaign targeted those who live near or routinely cross the Rwanda/DRC border and unvaccinated first responders. Children p < 0.05) to be lost between the first and second dose. Most individuals who were ineligible for the second dose were women who fell pregnant after the first dose. Conclusions: Findings highlight that a large-scale vaccination campaign, including remote areas, is feasible with high adherence despite the concurrent COVID-19 pandemic. Early stakeholder engagement and local leadership were critical to success. Future studies of reasons for non-adherence, as well as strategies to integrate family planning into campaign activities to reduce ineligibility due to pregnancy, are warranted.
- Open Access
Performance of an evidence-based risk algorithm to diagnose chlamydia and gonorrhea among pregnant Rwandan women
Reproductive tract infections (RTI) are associated with adverse outcomes in pregnant African women. However, many diagnostic strategies are unaffordable or perform poorly. Here, we assess RTI prevalence and predictors of chlamydia/gonorrhea (CT/NG) in pregnant women reporting vaginal discharge and the performance of our previously published CT/NG risk algorithm in this population versus Rwandan National Guidelines (RNG). From 2017-2020, free sexually transmitted infections (STI) services were provided to residents in Kigali, Rwanda. Medical history and gynecologic examination were done. Laboratory assessments included HIV; syphilis; microscopy for trichomoniasis, bacterial vaginosis (BV), and candida; and PCR for CT/NG. Eighty-seven pregnant women received STI services. Prevalence was 28% for CT/NG, 15% for trichomoniasis, 24% for BV, 39% for candida, and 79% for any RTI. Predictors of CT/NG were age <=25 (adjusted prevalence odds ratio [aPOR]=4.92; 95% confidence interval [CI]: 1.52-15.90; p=0.008), inconsistent condom use (aPOR=4.86; 95%CI: 0.98-24.10; p=0.053), absence of candida (aPOR=4.23; 95%CI: 1.13-15.82; p=0.032), and endocervical inflammation/discharge (aPOR=4.91; 95%CI: 1.40-17.20; p=0.013). Our algorithm outperformed the 2019 and 2024 RNG (sensitivity: 92% versus 46% and 35% respectively). Pregnant women seeking STI services had high RTI prevalence. Our algorithm performed well. Algorithms tailored for pregnant women and including male partner risk factors should be explored.
Open AccessPerformance of an evidence-based risk algorithm to diagnose chlamydia and gonorrhea among pregnant Rwandan women
Reproductive tract infections (RTI) are associated with adverse outcomes in pregnant African women. However, many diagnostic strategies are unaffordable or perform poorly. Here, we assess RTI prevalence and predictors of chlamydia/gonorrhea (CT/NG) in pregnant women reporting vaginal discharge and the performance of our previously published CT/NG risk algorithm in this population versus Rwandan National Guidelines (RNG). From 2017-2020, free sexually transmitted infections (STI) services were provided to residents in Kigali, Rwanda. Medical history and gynecologic examination were done. Laboratory assessments included HIV; syphilis; microscopy for trichomoniasis, bacterial vaginosis (BV), and candida; and PCR for CT/NG. Eighty-seven pregnant women received STI services. Prevalence was 28% for CT/NG, 15% for trichomoniasis, 24% for BV, 39% for candida, and 79% for any RTI. Predictors of CT/NG were age <=25 (adjusted prevalence odds ratio [aPOR]=4.92; 95% confidence interval [CI]: 1.52-15.90; p=0.008), inconsistent condom use (aPOR=4.86; 95%CI: 0.98-24.10; p=0.053), absence of candida (aPOR=4.23; 95%CI: 1.13-15.82; p=0.032), and endocervical inflammation/discharge (aPOR=4.91; 95%CI: 1.40-17.20; p=0.013). Our algorithm outperformed the 2019 and 2024 RNG (sensitivity: 92% versus 46% and 35% respectively). Pregnant women seeking STI services had high RTI prevalence. Our algorithm performed well. Algorithms tailored for pregnant women and including male partner risk factors should be explored.
- 15 April 2026
- Published by Elsevier in Annals of Epidemiology
- Vol. 119, 110097
Advancing systems thinking in implementation science: An epidemiologic perspective
- 15 April 2026
- Published by Elsevier in Annals of Epidemiology
- Vol. 119, 110097
Advancing systems thinking in implementation science: An epidemiologic perspective
- Open Access
- 20 February 2026
- Published by Public Library of Science (PLoS) in PLOS Digital Health
- Vol. 5 (2) , e0001255
AID-FGS: Artificial intelligence-enabled diagnosis of female genital schistosomiasis: Preliminary findings
Female genital schistosomiasis (FGS) is a sequela of infection with a waterborne parasite prevalent in sub-Saharan Africa and is associated with increased HIV risk. Diagnosis of FGS involves visual colposcopic identification of lesions on the cervix or vaginal walls. Previous studies have utilized digital image processing methods with statistical validation, and more recently, an artificial intelligence (AI)-based approach has also been explored. In this work, we sought to evaluate the performance of an AI model for identifying the presence of FGS from cervical photographs. Colposcopy images were obtained from 340 subjects in Zambia. Ground truth for presence or absence of FGS was determined by trained expert human examiners using visual assessment of images. Examiners also provided a FGS severity score between 0–8 for each image based on the number of lesions and the cervical quadrants affected, where 8 denotes highest severity and 0 denotes no FGS. The images were pre-processed with specular reflection artifact removal and image cropping to focus on the regions corresponding to the cervix and the transformation zone. The preprocessed dataset was randomly divided into training (FGS = 71, no FGS = 71) and testing (FGS = 21, no FGS = 177) cohorts. Image representations in the latent space were obtained using an ensemble of pre-trained machine learning models to further classify the image into FGS and no FGS. The best performance in the testing dataset was obtained at subject-level with area under the curve (AUC) =0.70 (95% Confidence interval: 0.58 - 0.82), Specificity = 0.68, and Sensitivity = 0.71, against the ground truth. Subjects with higher FGS severity scores (between 5–8) had high prediction rate by the machine classifier compared to those with lower severity scores (between 1–4). Machine learning shows promise in detecting FGS from limited colposcopy images. Early, accurate diagnosis may enhance reproductive health, and reduce HIV transmission risks, safeguarding maternal and child health. Female genital schistosomiasis is a disease caused by a waterborne parasite Schistosoma haematobium, affecting millions of women in sub-Saharan Africa. It can lead to serious health problems and increases the risk of contracting HIV. Diagnosing this condition currently depends on a detailed visual exam of the cervix, performed by highly trained specialists. But these experts are scarce, and even among them, there can be disagreement when identifying the disease. In our study, we explored whether a computer-based system could help solve this problem. We used photos taken during medical exams to recognize patterns linked to the disease. This type of learning based on patterns in images is similar to how humans learn to recognize faces or objects. We found that the computer model was able to identify the disease with a level of accuracy that is encouraging, especially when the disease was more severe. This shows that technology can play a meaningful role in bringing better healthcare to places where expert diagnosis isn’t always available. Our hope is that this approach will lead to quicker, more reliable detection, helping protect the health of women and reduce their risk of HIV.
- 20 February 2026
- Published by Public Library of Science (PLoS) in PLOS Digital Health
- Vol. 5 (2) , e0001255
Open AccessAID-FGS: Artificial intelligence-enabled diagnosis of female genital schistosomiasis: Preliminary findings
Female genital schistosomiasis (FGS) is a sequela of infection with a waterborne parasite prevalent in sub-Saharan Africa and is associated with increased HIV risk. Diagnosis of FGS involves visual colposcopic identification of lesions on the cervix or vaginal walls. Previous studies have utilized digital image processing methods with statistical validation, and more recently, an artificial intelligence (AI)-based approach has also been explored. In this work, we sought to evaluate the performance of an AI model for identifying the presence of FGS from cervical photographs. Colposcopy images were obtained from 340 subjects in Zambia. Ground truth for presence or absence of FGS was determined by trained expert human examiners using visual assessment of images. Examiners also provided a FGS severity score between 0–8 for each image based on the number of lesions and the cervical quadrants affected, where 8 denotes highest severity and 0 denotes no FGS. The images were pre-processed with specular reflection artifact removal and image cropping to focus on the regions corresponding to the cervix and the transformation zone. The preprocessed dataset was randomly divided into training (FGS = 71, no FGS = 71) and testing (FGS = 21, no FGS = 177) cohorts. Image representations in the latent space were obtained using an ensemble of pre-trained machine learning models to further classify the image into FGS and no FGS. The best performance in the testing dataset was obtained at subject-level with area under the curve (AUC) =0.70 (95% Confidence interval: 0.58 - 0.82), Specificity = 0.68, and Sensitivity = 0.71, against the ground truth. Subjects with higher FGS severity scores (between 5–8) had high prediction rate by the machine classifier compared to those with lower severity scores (between 1–4). Machine learning shows promise in detecting FGS from limited colposcopy images. Early, accurate diagnosis may enhance reproductive health, and reduce HIV transmission risks, safeguarding maternal and child health. Female genital schistosomiasis is a disease caused by a waterborne parasite Schistosoma haematobium, affecting millions of women in sub-Saharan Africa. It can lead to serious health problems and increases the risk of contracting HIV. Diagnosing this condition currently depends on a detailed visual exam of the cervix, performed by highly trained specialists. But these experts are scarce, and even among them, there can be disagreement when identifying the disease. In our study, we explored whether a computer-based system could help solve this problem. We used photos taken during medical exams to recognize patterns linked to the disease. This type of learning based on patterns in images is similar to how humans learn to recognize faces or objects. We found that the computer model was able to identify the disease with a level of accuracy that is encouraging, especially when the disease was more severe. This shows that technology can play a meaningful role in bringing better healthcare to places where expert diagnosis isn’t always available. Our hope is that this approach will lead to quicker, more reliable detection, helping protect the health of women and reduce their risk of HIV.
- Open Access
- 16 January 2026
- Published by International Society of Global Health in Journal of Global Health
- Vol. 16, 03002
Imported female genital schistosomiasis: a neglected health issue across borders
Female genital schistosomiasis (FGS) is one of the most neglected tropical diseases (NTDs) in the world, affecting more than 56 million women and girls in Africa alone, where 90% of cases occur [1]. It is characterised by lesions on the cervix and other reproductive structures that develop after infection with Schistosoma haematobium, a parasitic trematode […]
- 16 January 2026
- Published by International Society of Global Health in Journal of Global Health
- Vol. 16, 03002
Open AccessImported female genital schistosomiasis: a neglected health issue across borders
Female genital schistosomiasis (FGS) is one of the most neglected tropical diseases (NTDs) in the world, affecting more than 56 million women and girls in Africa alone, where 90% of cases occur [1]. It is characterised by lesions on the cervix and other reproductive structures that develop after infection with Schistosoma haematobium, a parasitic trematode […]
- Open Access
- 30 December 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (12) , e0338627
Implementing postpartum family planning services in rural Rwanda: A mixed-methods study
Introduction: Postpartum family planning (PPFP) reduces adverse maternal-child outcomes related to short interpregnancy intervals and unintended pregnancies. This mixed-method study assessed PPFP needs in rural government health facilities as well as clients’ knowledge and barriers to PPFP uptake in Rwanda. Methods: From May-July 2023, we conducted cross-sectional PPFP needs assessments in rural government health facilities and focus group discussions (FGDs) among couples attending antenatal clinics to understand women’s and men’s perceptions and barriers to PPFP uptake. Quantitative data were collected from twelve rural government health facilities (two hospitals, four health centers, six health posts). Qualitative data were collected during six FGD with 6–12 participants per session. Quantitative data were analyzed descriptively, and qualitative data were analyzed thematically with a deductive approach. Results: Seventeen (65%) hospital nurses and 11 (23%) health center nurses were trained in implant insertion, and six (23%) hospital nurses and four (9%) health center nurses were trained in postpartum intrauterine device (PPIUD) insertion. Hospitals provided an average of 204 postpartum implants (29% of deliveries) and seven PPIUDs per month (1% of deliveries), while health centers provided 25 postpartum implants and no PPIUDs per month. At health posts, there was no equipment for implant or intrauterine device (IUD) provision. FGD findings revealed that couples have access to family planning counseling at the health center, but they were concerned about limited information on contraceptive method mechanisms of action and side effects; knowledge about and access to IUD/PPIUD was especially limited. Conclusions: Enhanced PPFP training and provision is needed in rural areas, especially for PPIUD. Knowledge gaps and concerns about side effects were emphasized in FGDs. PPFP demand creation strategies tailored for the rural populace as well as rural provider training could improve PPFP access and uptake in rural government clinics of Rwanda.
- 30 December 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (12) , e0338627
Open AccessImplementing postpartum family planning services in rural Rwanda: A mixed-methods study
Introduction: Postpartum family planning (PPFP) reduces adverse maternal-child outcomes related to short interpregnancy intervals and unintended pregnancies. This mixed-method study assessed PPFP needs in rural government health facilities as well as clients’ knowledge and barriers to PPFP uptake in Rwanda. Methods: From May-July 2023, we conducted cross-sectional PPFP needs assessments in rural government health facilities and focus group discussions (FGDs) among couples attending antenatal clinics to understand women’s and men’s perceptions and barriers to PPFP uptake. Quantitative data were collected from twelve rural government health facilities (two hospitals, four health centers, six health posts). Qualitative data were collected during six FGD with 6–12 participants per session. Quantitative data were analyzed descriptively, and qualitative data were analyzed thematically with a deductive approach. Results: Seventeen (65%) hospital nurses and 11 (23%) health center nurses were trained in implant insertion, and six (23%) hospital nurses and four (9%) health center nurses were trained in postpartum intrauterine device (PPIUD) insertion. Hospitals provided an average of 204 postpartum implants (29% of deliveries) and seven PPIUDs per month (1% of deliveries), while health centers provided 25 postpartum implants and no PPIUDs per month. At health posts, there was no equipment for implant or intrauterine device (IUD) provision. FGD findings revealed that couples have access to family planning counseling at the health center, but they were concerned about limited information on contraceptive method mechanisms of action and side effects; knowledge about and access to IUD/PPIUD was especially limited. Conclusions: Enhanced PPFP training and provision is needed in rural areas, especially for PPIUD. Knowledge gaps and concerns about side effects were emphasized in FGDs. PPFP demand creation strategies tailored for the rural populace as well as rural provider training could improve PPFP access and uptake in rural government clinics of Rwanda.
- Open Access
- 8 September 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (11) , 3899-3906
Heterologous two-dose Ebola vaccine regimen in pregnant women in Rwanda: a randomized controlled phase 3 trial
Risk of death for both mother and fetus following Ebola virus infection is extremely high. In this study, healthy women in Rwanda aged ≥18 years were randomized to two-dose Ebola vaccination (Ad26.ZEBOV, MVA-BN-Filo) during pregnancy (group A) or postpartum (group B). Unvaccinated pregnant group B women served as control. This was a parallel, randomized, controlled, open-label, single-center trial to evaluate the safety (primary endpoint—outcomes of interest and serious adverse events (SAEs)) and immunogenicity (secondary endpoint) of the two-dose Ebola vaccination. Among 3,484 women screened, 2,013 were randomized, and 2,012 women and 1,945 infants born alive were descriptively analyzed. Adverse outcomes of interest occurred in women (5.2% in group A and 7.3% in group B) and infants (26.0% in group A and 25.6% in group B). The most common maternal outcome of interest was pathways to preterm birth (3.2% in group A and 3.4% in group B), and the most common infant outcome of interest was small for gestational age (14.3% in group A and 11.8% in group B). Maternal/fetal and neonatal/infant SAE frequencies were comparable between groups (9.8% in group A, 9.0% in group B and 21.9% in group A, 15.9% in group B, respectively). Anti-Ebola virus glycoprotein-specific binding antibody response (secondary endpoint) was sustained in ≥90% of women at 1 year postdose 1. In group A, binding antibodies were detected in cord blood (99%) and infant serum (95%) samples 14 weeks postbirth. The trial met all primary and secondary objectives. Ad26.ZEBOV, MVA-BN-Filo did not raise concerns regarding adverse maternal/fetal or neonatal/infant outcomes, had no unexpected safety issues, and induced binding antibody responses in women and offspring through passive transfer. ClinicalTrials.gov registration: NCT04556526.
- 8 September 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (11) , 3899-3906
Open AccessHeterologous two-dose Ebola vaccine regimen in pregnant women in Rwanda: a randomized controlled phase 3 trial
Risk of death for both mother and fetus following Ebola virus infection is extremely high. In this study, healthy women in Rwanda aged ≥18 years were randomized to two-dose Ebola vaccination (Ad26.ZEBOV, MVA-BN-Filo) during pregnancy (group A) or postpartum (group B). Unvaccinated pregnant group B women served as control. This was a parallel, randomized, controlled, open-label, single-center trial to evaluate the safety (primary endpoint—outcomes of interest and serious adverse events (SAEs)) and immunogenicity (secondary endpoint) of the two-dose Ebola vaccination. Among 3,484 women screened, 2,013 were randomized, and 2,012 women and 1,945 infants born alive were descriptively analyzed. Adverse outcomes of interest occurred in women (5.2% in group A and 7.3% in group B) and infants (26.0% in group A and 25.6% in group B). The most common maternal outcome of interest was pathways to preterm birth (3.2% in group A and 3.4% in group B), and the most common infant outcome of interest was small for gestational age (14.3% in group A and 11.8% in group B). Maternal/fetal and neonatal/infant SAE frequencies were comparable between groups (9.8% in group A, 9.0% in group B and 21.9% in group A, 15.9% in group B, respectively). Anti-Ebola virus glycoprotein-specific binding antibody response (secondary endpoint) was sustained in ≥90% of women at 1 year postdose 1. In group A, binding antibodies were detected in cord blood (99%) and infant serum (95%) samples 14 weeks postbirth. The trial met all primary and secondary objectives. Ad26.ZEBOV, MVA-BN-Filo did not raise concerns regarding adverse maternal/fetal or neonatal/infant outcomes, had no unexpected safety issues, and induced binding antibody responses in women and offspring through passive transfer. ClinicalTrials.gov registration: NCT04556526.
- Open Access
- 23 July 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14, e69540
Evaluating the Effectiveness of a Mobile HIV Prevention App to Increase HIV and Sexually Transmitted Infection Testing and Pre-Exposure Prophylaxis Initiation Among Rural Men Who Have Sex With Men in the Southern United States: Protocol for a Randomized Controlled Trial
Background: Gay and bisexual men who have sex with men (MSM) in the rural United States are less likely to test for HIV and sexually transmitted infections (STIs) and use pre-exposure prophylaxis (PrEP) compared to urban MSM. Given the challenges in building brick-and-mortar facilities serving the sexual health needs of MSM in rural communities, there is a need to evaluate digital engagement strategies. Combine is a smartphone app designed to provide HIV prevention information and resources to MSM that may be particularly well suited to support rural MSM. HealthMindr, an app from which Combine is adapted, has previously been shown to increase HIV testing and PrEP uptake among urban MSM. Because rural MSM face additional barriers to accessing HIV prevention services, a motivational interview (MI) focused on HIV prevention strategies might enhance the effectiveness of Combine to increase uptake of HIV testing, STI testing, and PrEP. Objective: This study aims to determine the effectiveness of the Combine app to increase HIV testing, STI testing, and PrEP initiation among rural cisgender MSM. We will also assess the effectiveness of 2 adjunctive interventions: the availability of free HIV and STI self-test kits and the offering of an MI. Methods: In this type 2 hybrid effectiveness-implementation randomized controlled trial, we will assess the effectiveness of Combine to increase HIV testing, STI testing, and PrEP initiation among rural MSM across the Southern United States. A total of 464 men will be recruited and randomized to 1 of the 4 arms. Participants in all 4 arms will have access to most app features (eg, health resources, quizzes, health care provider locators, and ordering free condoms and lubricants). Using a 2×2 factorial design, half (232/464, 50%) of the participants will be randomized to receive access to free at-home HIV and STI self-test kits and half (232/464, 50%) will be randomized to receive an MI. Participants will complete surveys every 6 months to allow for assessment of self-reported outcomes: app use, HIV testing, STI testing, and PrEP initiation over the 24-month follow-up period. Self-reported PrEP uptake will be verified by dried blood spot testing or uploading a photograph of a PrEP prescription. Results: Participant recruitment began in March 2024. As of July 2025, 395 participants have been enrolled and randomized. Recruitment is expected to be completed by December 2025. Conclusions: This trial will determine whether the Combine app increases HIV testing, STI testing, and PrEP uptake among rural MSM in the Southern United States. It will also provide critical information about the most effective strategies for implementing digital health interventions for rural MSM. Trial Registration: ClinicalTrials.gov NCT06205368; https://clinicaltrials.gov/study/NCT06205368 International Registered Report Identifier (IRRID): DERR1-10.2196/69540
- 23 July 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14, e69540
Open AccessEvaluating the Effectiveness of a Mobile HIV Prevention App to Increase HIV and Sexually Transmitted Infection Testing and Pre-Exposure Prophylaxis Initiation Among Rural Men Who Have Sex With Men in the Southern United States: Protocol for a Randomized Controlled Trial
Background: Gay and bisexual men who have sex with men (MSM) in the rural United States are less likely to test for HIV and sexually transmitted infections (STIs) and use pre-exposure prophylaxis (PrEP) compared to urban MSM. Given the challenges in building brick-and-mortar facilities serving the sexual health needs of MSM in rural communities, there is a need to evaluate digital engagement strategies. Combine is a smartphone app designed to provide HIV prevention information and resources to MSM that may be particularly well suited to support rural MSM. HealthMindr, an app from which Combine is adapted, has previously been shown to increase HIV testing and PrEP uptake among urban MSM. Because rural MSM face additional barriers to accessing HIV prevention services, a motivational interview (MI) focused on HIV prevention strategies might enhance the effectiveness of Combine to increase uptake of HIV testing, STI testing, and PrEP. Objective: This study aims to determine the effectiveness of the Combine app to increase HIV testing, STI testing, and PrEP initiation among rural cisgender MSM. We will also assess the effectiveness of 2 adjunctive interventions: the availability of free HIV and STI self-test kits and the offering of an MI. Methods: In this type 2 hybrid effectiveness-implementation randomized controlled trial, we will assess the effectiveness of Combine to increase HIV testing, STI testing, and PrEP initiation among rural MSM across the Southern United States. A total of 464 men will be recruited and randomized to 1 of the 4 arms. Participants in all 4 arms will have access to most app features (eg, health resources, quizzes, health care provider locators, and ordering free condoms and lubricants). Using a 2×2 factorial design, half (232/464, 50%) of the participants will be randomized to receive access to free at-home HIV and STI self-test kits and half (232/464, 50%) will be randomized to receive an MI. Participants will complete surveys every 6 months to allow for assessment of self-reported outcomes: app use, HIV testing, STI testing, and PrEP initiation over the 24-month follow-up period. Self-reported PrEP uptake will be verified by dried blood spot testing or uploading a photograph of a PrEP prescription. Results: Participant recruitment began in March 2024. As of July 2025, 395 participants have been enrolled and randomized. Recruitment is expected to be completed by December 2025. Conclusions: This trial will determine whether the Combine app increases HIV testing, STI testing, and PrEP uptake among rural MSM in the Southern United States. It will also provide critical information about the most effective strategies for implementing digital health interventions for rural MSM. Trial Registration: ClinicalTrials.gov NCT06205368; https://clinicaltrials.gov/study/NCT06205368 International Registered Report Identifier (IRRID): DERR1-10.2196/69540
- 1 July 2025
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 99 (3) , 311-319
Cost and Cost-Effectiveness of Online Recruitment to Increase HIV Self-Testing Among Black and Hispanic/Latino Men Who Have Sex With Men in the United States, 2020–2021
Background: Black or African American and Hispanic/Latino gay, bisexual, and other men who have sex with men (BMSM and HLMSM) in the United States are disproportionately affected by HIV. We analyze the cost and cost-effectiveness of HIV self-testing through online recruitment of BMSM and HLMSM into an HIV self-testing study. Setting: Eleven US states, February 2020–February 2021. Methods: BMSM and HLMSM aged ≥18 years without previous HIV diagnosis or current pre-exposure prophylaxis use were recruited through dating and general interest websites/apps (sites). Using the health care provider perspective and a 16-month timeframe, we assessed economic costs (2022 US Dollars) of online recruitment, HIV self-test (HIVST) distribution, and participant support. A time–motion study tracked staff time spent on study implementation activities. We reported incremental program cost, cost per HIVST used, and cost per new HIV diagnosis comparing recruitment through dating versus general interest sites. Results: The total cost was $275,776 to enroll 1306 participants through dating sites, and support 1005 MSM who used an HIVST (11.74% positivity). The total cost was $168,099 to enroll 600 participants through general interest sites, and support 511 MSM who used an HIVST (5.48% positivity). Recruitment through dating versus general interest sites was more costly and more effective, with incremental cost-effectiveness ratios of $218/HIVST used and $1196/new diagnosis, relatively low cost per new HIV diagnosis compared with those estimated in other HIV testing interventions. Incremental cost-effectiveness ratios were higher for HLMSM versus BMSM. Conclusions: HIV self-testing through dating and general interest site recruitment may be an effective and cost-effective approach to increase new HIV diagnoses.
- 1 July 2025
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 99 (3) , 311-319
Cost and Cost-Effectiveness of Online Recruitment to Increase HIV Self-Testing Among Black and Hispanic/Latino Men Who Have Sex With Men in the United States, 2020–2021
Background: Black or African American and Hispanic/Latino gay, bisexual, and other men who have sex with men (BMSM and HLMSM) in the United States are disproportionately affected by HIV. We analyze the cost and cost-effectiveness of HIV self-testing through online recruitment of BMSM and HLMSM into an HIV self-testing study. Setting: Eleven US states, February 2020–February 2021. Methods: BMSM and HLMSM aged ≥18 years without previous HIV diagnosis or current pre-exposure prophylaxis use were recruited through dating and general interest websites/apps (sites). Using the health care provider perspective and a 16-month timeframe, we assessed economic costs (2022 US Dollars) of online recruitment, HIV self-test (HIVST) distribution, and participant support. A time–motion study tracked staff time spent on study implementation activities. We reported incremental program cost, cost per HIVST used, and cost per new HIV diagnosis comparing recruitment through dating versus general interest sites. Results: The total cost was $275,776 to enroll 1306 participants through dating sites, and support 1005 MSM who used an HIVST (11.74% positivity). The total cost was $168,099 to enroll 600 participants through general interest sites, and support 511 MSM who used an HIVST (5.48% positivity). Recruitment through dating versus general interest sites was more costly and more effective, with incremental cost-effectiveness ratios of $218/HIVST used and $1196/new diagnosis, relatively low cost per new HIV diagnosis compared with those estimated in other HIV testing interventions. Incremental cost-effectiveness ratios were higher for HLMSM versus BMSM. Conclusions: HIV self-testing through dating and general interest site recruitment may be an effective and cost-effective approach to increase new HIV diagnoses.
- Open Access
Excess HIV infections and costs associated with reductions in HIV prevention services in the United States: Projection using real-world data
Importance Pre-exposure prophylaxis (PrEP) is a proven effective intervention to reduce risk for HIV infection, but changes in policies that lead to increased out of pocket PrEP costs or that decrease access to convenient PrEP locations could reduce PrEP coverage, resulting in excess HIV infections and costs. Objective To estimate the impacts of federal policy changes on PrEP coverage, new HIV infections and costs associated with new HIV infections Design Estimation of excess HIV infections under different policy impacts were conducted using parameters from a previously published ecological model of the relationship between PrEP coverage and new HIV infections. Costs were estimated for the treatment of infections not averted under different scenarios. Setting United States Participants There was no individual participation in research activities; population-based data sources were used to describe the population-level PrEP use and new diagnoses under different hypothetical changes in PrEP coverage. Exposures Percent of people with indications for PrEP who are taking PrEP Main Outcome and Measures Estimated change in new HIV infections under different assumptions of change in PrEP coverage; costs of treatment for avoidable HIV infections and net costs of avoidable infections after accounting for costs of PrEP medications. Results Even modest reductions in PrEP coverage would result in thousands of avoidable HIV infections. An absolute 3.3% annual reduction in PrEP coverage over the next decade would result in 8,618 avoidable HIV infections, with lifetime medical costs of over $3.6 billion (discounted) for treatment of the unaverted HIV infections. Conclusions and Relevance Changes in policy that reduce PrEP uptake would result in avoidable HIV infections and increased costs for HIV treatment. Maintaining policies and programs that support PrEP uptake offers benefits for health and is estimated to result in net cost savings. Question What are the likely impacts on HIV transmissions and healthcare costs if policy changes result in decreased PrEP utilization in the United States? Findings Under assumptions of even modest reductions in PrEP use, we estimated thousands of HIV infections would fail to be averted over the next decade, and billions of dollars of additional treatment costs would accrue to the healthcare system. Results of the study We used historical descriptive data on the US HIV epidemic to quantify the relationship between PrEP coverage and trends in HIV diagnoses and to estimate future trends in HIV infections if PrEP coverage were to be rolled back. If PrEP use declines modestly – about 3% annually – we estimate that 8,618 new infections would fail to be averted in a decade because of lowered PrEP uptake, and the estimated lifetime medical costs of these unaverted infections would be $3.6 billion (discounted) and $9.3 billion (undiscounted). Meaning Changes in healthcare priorities and policies, especially those that increase out of pocket costs of PrEP or reduce the convenience of engaging in PrEP care, risk rolling back our progress in ending the HIV epidemic, accruing avertable HIV infections, and incurring increased costs for medical care of people whose HIV infections were avoidable.
Open AccessExcess HIV infections and costs associated with reductions in HIV prevention services in the United States: Projection using real-world data
Importance Pre-exposure prophylaxis (PrEP) is a proven effective intervention to reduce risk for HIV infection, but changes in policies that lead to increased out of pocket PrEP costs or that decrease access to convenient PrEP locations could reduce PrEP coverage, resulting in excess HIV infections and costs. Objective To estimate the impacts of federal policy changes on PrEP coverage, new HIV infections and costs associated with new HIV infections Design Estimation of excess HIV infections under different policy impacts were conducted using parameters from a previously published ecological model of the relationship between PrEP coverage and new HIV infections. Costs were estimated for the treatment of infections not averted under different scenarios. Setting United States Participants There was no individual participation in research activities; population-based data sources were used to describe the population-level PrEP use and new diagnoses under different hypothetical changes in PrEP coverage. Exposures Percent of people with indications for PrEP who are taking PrEP Main Outcome and Measures Estimated change in new HIV infections under different assumptions of change in PrEP coverage; costs of treatment for avoidable HIV infections and net costs of avoidable infections after accounting for costs of PrEP medications. Results Even modest reductions in PrEP coverage would result in thousands of avoidable HIV infections. An absolute 3.3% annual reduction in PrEP coverage over the next decade would result in 8,618 avoidable HIV infections, with lifetime medical costs of over $3.6 billion (discounted) for treatment of the unaverted HIV infections. Conclusions and Relevance Changes in policy that reduce PrEP uptake would result in avoidable HIV infections and increased costs for HIV treatment. Maintaining policies and programs that support PrEP uptake offers benefits for health and is estimated to result in net cost savings. Question What are the likely impacts on HIV transmissions and healthcare costs if policy changes result in decreased PrEP utilization in the United States? Findings Under assumptions of even modest reductions in PrEP use, we estimated thousands of HIV infections would fail to be averted over the next decade, and billions of dollars of additional treatment costs would accrue to the healthcare system. Results of the study We used historical descriptive data on the US HIV epidemic to quantify the relationship between PrEP coverage and trends in HIV diagnoses and to estimate future trends in HIV infections if PrEP coverage were to be rolled back. If PrEP use declines modestly – about 3% annually – we estimate that 8,618 new infections would fail to be averted in a decade because of lowered PrEP uptake, and the estimated lifetime medical costs of these unaverted infections would be $3.6 billion (discounted) and $9.3 billion (undiscounted). Meaning Changes in healthcare priorities and policies, especially those that increase out of pocket costs of PrEP or reduce the convenience of engaging in PrEP care, risk rolling back our progress in ending the HIV epidemic, accruing avertable HIV infections, and incurring increased costs for medical care of people whose HIV infections were avoidable.